Intellia Therapeutics's banner

Intellia Therapeutics

@intelliatx • 12,248 subscribers

We're a #GeneEditing company, developing novel, potentially curative therapeutics leveraging #CRISPR-based technologies. Guidelines: https://t.co/u2gHl9Tmgr

Shorts

📢 $NTLA News: And so the countdown begins... We are proud to share the FDA has accepted Intellia's Biologics License Application (BLA) with Priority Review for our potential one-time #hereditaryangioedema treatment. The PDUFA target action date is March 10, 2027. Read the full announcement:

📢 $NTLA News: And so the countdown begins... We are proud to share the FDA has accepted Intellia's Biologics License Application (BLA) with Priority Review for our potential one-time #hereditaryangioedema treatment. The PDUFA target action date is March 10, 2027. Read the full announcement:

15,101 次观看

#ATTR News: Intellia doses the first patient in its Phase 3 MAGNITUDE study of NTLA-2001 for the potential treatment of #transthyretinamyloidosis with cardiomyopathy: #GeneEditing #CRISPR

#ATTR News: Intellia doses the first patient in its Phase 3 MAGNITUDE study of NTLA-2001 for the potential treatment of #transthyretinamyloidosis with cardiomyopathy: #GeneEditing #CRISPR

26,660 次观看

#ATTR News: $NTLA announces positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) in patients with #ATTR amyloidosis with cardiomyopathy. Full details here: Join us at 12 p.m. ET for a webcast discussing the data, as well as an update from the ongoing Phase 1 polyneuropathy cohort. #CRISPR #GeneEditing

#ATTR News: $NTLA announces positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) in patients with #ATTR amyloidosis with cardiomyopathy. Full details here: Join us at 12 p.m. ET for a webcast discussing the data, as well as an update from the ongoing Phase 1 polyneuropathy cohort. #CRISPR #GeneEditing

19,292 次观看

NEWS: $NTLA receives authorization by the MHRAgovuk to initiate a Phase 1/2 of NTLA-3001 for the treatment of #alpha1 antitrypsin deficiency-associated lung disease. This is Intellia's first wholly owned in vivo gene insertion program. #CRISPR #AATD

NEWS: $NTLA receives authorization by the MHRAgovuk to initiate a Phase 1/2 of NTLA-3001 for the treatment of #alpha1 antitrypsin deficiency-associated lung disease. This is Intellia's first wholly owned in vivo gene insertion program. #CRISPR #AATD

19,072 次观看

$NTLA News: We are pleased to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of #ATTR #amyloidosis with polyneuropathy: #CRISPR #GeneEditing

$NTLA News: We are pleased to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of #ATTR #amyloidosis with polyneuropathy: #CRISPR #GeneEditing

14,242 次观看

Congratulations to Vertex Pharmaceuticals and CRISPR Therapeutics for achieving the first-ever MHRAgovuk approval of a #CRISPR therapy. This historic milestone is paving the way for the future of #geneediting.

Congratulations to Vertex Pharmaceuticals and CRISPR Therapeutics for achieving the first-ever MHRAgovuk approval of a #CRISPR therapy. This historic milestone is paving the way for the future of #geneediting.

16,935 次观看

Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at EAACI 2024 Congress. Full details here: #HAE #CRISPR #geneediting

Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at EAACI 2024 Congress. Full details here: #HAE #CRISPR #geneediting

13,400 次观看

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

#ATTR News: FDA cleared Intellia’s NTLA-2001 IND application to enter late-stage clinical development for the treatment of #transthyretinamyloidosis with cardiomyopathy: NTLA-2001 is the first-ever investigational in vivo therapy cleared by FDA to enter a Phase 3 trial. #CRISPR #GeneEditing

#ATTR News: FDA cleared Intellia’s NTLA-2001 IND application to enter late-stage clinical development for the treatment of #transthyretinamyloidosis with cardiomyopathy: NTLA-2001 is the first-ever investigational in vivo therapy cleared by FDA to enter a Phase 3 trial. #CRISPR #GeneEditing

Intellia Therapeutics

68,131 次观看 • 2 年前

Great way to wrap up a historic week! We’re honored to light up the iconic Nasdaq Tower in Times Square celebrating Intellia's recent #CRISPR milestone. A big thanks to Nasdaq for recognizing our recent HAELO topline data, a first ever for in vivo #geneediting.

Great way to wrap up a historic week! We’re honored to light up the iconic Nasdaq Tower in Times Square celebrating Intellia's recent #CRISPR milestone. A big thanks to Nasdaq for recognizing our recent HAELO topline data, a first ever for in vivo #geneediting.

Intellia Therapeutics

14,512 次观看 • 5 个月前

Congratulations to Vertex Pharmaceuticals and CRISPR Therapeutics for achieving the first-ever MHRAgovuk approval of a #CRISPR therapy. This historic milestone is paving the way for the future of #geneediting.

Congratulations to Vertex Pharmaceuticals and CRISPR Therapeutics for achieving the first-ever MHRAgovuk approval of a #CRISPR therapy. This historic milestone is paving the way for the future of #geneediting.

Intellia Therapeutics

16,935 次观看 • 2 年前

没有更多内容可加载